Switching Tirzepatide Providers

What the data shows

Across the 16 programmes we price, all-in cost at a 10 mg maintenance dose runs from $215 to $597 for the identical molecule. The spread is overhead, clinical wrap, pharmacy sourcing and margin rather than the medicine.

What to do with it

Price the dose you expect to hold, including every recurring fee, and check the figure against the provider's own page before acting on it. Every programme page here links that page directly.

What we could not establish

Shipping reliability, response times and clinical quality. None is measurable from outside, so none appears in our tables rather than being estimated.

What this changes about the programme you pick

Very little on its own, which is the honest answer. Almost every decision in this market comes back to three questions: what will I pay at the dose I actually hold, who compounds it, and what happens if I stop. A page that does not move one of those three is decoration.

Where this one moves the needle is on the first. Run the figure at your expected maintenance dose rather than the advertised one, and the ranking you were shown elsewhere frequently inverts.

How to check the numbers above

Every figure carries a capture date and an evidence status. Prices marked verified were read on the provider's own page; the rest came from named third-party sources and are treated as indicative. Open the dataset, re-sort it, and see whether our published order reproduces.

If it does not, that is a bug or a lie and you can find it without our help. If our figure and a provider's own page disagree, ours is wrong and we want to know.

What is deliberately absent

Shipping reliability, response times, and whether the clinical oversight is any good. We hold no measurements of those we would defend, so they appear nowhere in our tables rather than being estimated into a score.

That is why there is no rating out of ten on this site. A single number would compress price, disclosure, service and clinical depth into one figure and hide the weighting. We publish the inputs instead so you can weight them yourself.

What the spread tells you

All-in cost at a 10 mg maintenance dose runs from $215 to $597 across the 16 programmes we price. That is the identical molecule from the same category of licensed pharmacy, so the difference is overhead, clinical wrap, sourcing and margin rather than the medicine.

A 2.8-times spread on an identical product is unusual outside markets where buyers cannot easily compare, which is exactly the condition this site exists to remove.

Price the dose you will actually hold

The single most valuable correction anyone reading this can make. Advertised figures describe the 2.5 mg starter dose, which occupies about four weeks of a twelve-month course. Ten of your first twelve months are spent at or near a maintenance dose.

On a dose-scaled programme those are different numbers. On a flat programme they are not, which is the entire argument for flat pricing and the reason it is worth paying a little more at initiation for it.

The verification step most people skip

Ask which pharmacy fills the prescription, by name, then search your state board's licensee register for it. It is free, takes about two minutes, and fewer than a fifth of priced programmes publish enough to let you do it.

A programme that names a pharmacy has given you something checkable. One that describes a category has told you what it is not telling you. One that deflects has answered the question.

Two questions that settle most of it

What will I pay in total in month six at 10 mg, including every fee? A flat, all-inclusive programme answers in one sentence. A split-pricing programme needs three, because the answer depends on whether your insurance pays for the medication. A programme that cannot answer at all has told you something.

Which pharmacy fills it, and is the prescriber licensed in my state? Both are checkable against public registers, both are free, and neither requires you to trust us or the programme.

What a good answer looks like in writing

A figure with a dose attached. A named pharmacy with a state licence number. A cancellation notice period. A statement that the preparation is compounded and not FDA-approved. And a renewal rate that matches the rate you were quoted.

Getting those five in an email before you pay costs nothing and resolves almost every dispute that appears in complaint records for this category. The programmes that answer promptly are, in our reading of the public record, rarely the ones patients later write about.

How current this is

Prices captured 2026-08-05. Every figure on this page carries that date and an evidence status saying whether we read it at the provider or took it from a third party. Pricing in this market has moved repeatedly during 2026, and several large programmes stopped selling compounded tirzepatide entirely.

Treat any comparison older than a month — including this one — as needing a re-check before you act on it. The dataset is republished on every build.

The three numbers worth carrying away

The cheapest verified all-in cost at a maintenance dose: $215 a month, $2,580 for a first year. The share of priced programmes charging a mandatory recurring fee on top of medication: 5 of 16. And the share naming a dispensing pharmacy before purchase: fewer than a fifth.

Those three settle more purchasing decisions than any narrative comparison, and all three are reproducible from the file.

What most published comparisons get wrong about this

They compare advertised figures, which are not comparable to one another. One programme quotes medication only, another bundles a mandatory membership, a third quotes a promotional first month that reverts, a fourth reprices you as the dose climbs, and a fifth charges a programme fee with medication billed separately.

Ranking those five on their headline numbers produces an order that is wrong in a predictable direction: the programmes with the most aggressive fee structures look cheapest.

What the spread actually represents

All-in cost runs $215 to $597 a month for the same molecule from the same category of licensed pharmacy. That gap is not the medicine. It is overhead, clinical wrap, sourcing and margin, plus how aggressively a programme is willing to structure its fees.

5 of 16 charge a mandatory recurring fee and 12 hold one price at every strength. Those two facts explain most of the spread, and neither appears in a headline figure.

Where our numbers could be wrong

A programme changed its price after our capture date. A third-party figure we recorded does not survive checking. A promotional rate was published as a standing one. Or a programme publishes something we could not find.

All four are live risks and the first is near-certain over time. Every figure carries its capture date and a link to the source we read, so the check takes about two minutes and does not require trusting us.

Why the cheapest entries are the least reliable

Four distortions push in the same direction: a promotional first month quoted as a standing rate, a prepaid bundle rate quoted as monthly, a medication figure that excludes a mandatory membership, and occasionally a different molecule's price in the wrong column.

Every one of those makes a programme look cheaper than it is, which is why the bottom of any published table is where errors concentrate. It is also why we mark which figures we read at the provider and which we did not, rather than presenting one confident list.

Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward.

How to sanity-check any figure you find elsewhere

Three questions. What dose does it describe? Does it include every recurring fee? And when was it captured? A price failing any of the three is not comparable to the numbers here, and most published figures fail at least one.

Tirzepatide makes this worse than most categories because the same molecule sells under several brands at prices spanning more than fifteenfold. 'Tirzepatide costs X' is not a sentence that can be true without naming the product and the channel.

Reading a price like a clinician would

A clinician deciding whether a programme is workable asks three questions a price comparison usually skips. Can this patient stay on it long enough to reach a maintenance dose? Is the supply reliable enough that titration will not be interrupted? And is the prescriber reachable when the fourth-week nausea arrives?

Each maps to something checkable before enrolling. Long prepaid terms answer the first badly if money is tight. A single owned dispensing facility answers the second worse than several named partner pharmacies, because a programme with one supply route cannot reroute your prescription. And the care model answers the third: asynchronous messaging is adequate for most titration questions and inadequate for a few.

None of that appears in an advertised price, and all of it decides whether the price you chose is the price you end up paying.

What the GIP arm may be doing

GIP receptor agonism is the pharmacological difference between tirzepatide and the GLP-1-only agents, and its contribution is still being characterised. Proposed mechanisms include effects on adipose tissue insulin sensitivity, on central appetite pathways distinct from the GLP-1 route, and on the tolerability of GLP-1 agonism itself, which would allow effective exposure at doses that would otherwise be poorly tolerated.

This is an area of active research rather than settled science, and anyone stating the mechanism confidently is ahead of the literature. What is established is the outcome difference in the head-to-head trial; the explanation for it is not fully resolved.

The question worth asking before the price question

Whether you have a covered indication. Tirzepatide is approved for chronic weight management and, as Mounjaro, for type 2 diabetes; obstructive sleep apnoea in adults with obesity is an additional route. A covered prescription under a documented indication beats every cash route on this site, frequently by an order of magnitude.

Most people do this backwards: compare cash prices, enrol, then discover an indication they already qualified for. Establishing coverage first costs a phone call and can save four figures a year, which is more than any comparison table on this site will save you.